Updates, Insights & Perspectives

Summary Onconox Inc., a Princeton-based biotechnology company advancing precision oncology therapies, has relocated its corporate headquarters to Princeton Innovation Center BioLabs. The move places Onconox within one of New Jersey’s leading life sciences innovation hubs and supports the company’s transition into a clinical-stage biotech as it prepares to advance OCN001 into first-in-human studies in 2026. Onconox Inc., a biotechnology company developing precision, low-burden

Summary The JPM Healthcare Conference 2026 marked a clear shift in sentiment across the life sciences sector. After two years of constrained capital and valuation compression, investors and strategic buyers are cautiously re-engaging, supported by improving venture deployment, stabilizing interest rates and renewed M&A activity. However, funding remains selective, with a strong emphasis on execution, regulatory readiness and capital efficiency.   Drawing on direct commentary

Executive Summary Artificial intelligence (AI) has rapidly transitioned from an experimental tool to a core driver of modern drug development. In the specific domain of reformulation and repurposing — where developers aim to unlock new therapeutic potential from validated pharmacology — AI is proving especially transformative. By integrating data across chemistry, biology, clinical outcomes, and real-world evidence, AI systems can identify promising new indications, optimize

Executive Summary Artificial intelligence has become the most overused — and often misunderstood — term in modern biotech. Dozens of companies now claim to be “AI-driven”, yet only a small fraction have meaningfully integrated AI into the scientific and operational backbone of their organization. For many, AI is a slide deck accessory; for few, it is a strategic partner that shapes decision-making, compresses timelines, and de-risks development. As capital becomes more select

Executive Summary For more than half a century, drug development has centered on a single dominant paradigm: molecules as the primary drivers of therapeutic innovation. But the future is moving toward something fundamentally different — multi-modal therapeutic systems  that integrate drugs with localized delivery, AI-guided optimization, biomarkers, imaging, and patient-centric digital tools. These systems do not replace drug innovation; they amplify it , unlocking therapeuti

Executive Summary Glioblastoma (GBM) and many central nervous system (CNS) disorders remain among the most challenging conditions to treat, largely due to the inability of many therapeutics to cross the blood–brain barrier (BBB). As a result, researchers and clinicians have increasingly turned their attention toward nose-to-brain delivery — an approach that uses the unique anatomy of the nasal cavity to bypass the BBB and deliver therapeutics directly to the brain. This artic

Executive Summary The global biotech sector has entered one of its most capital-constrained periods in recent history. Venture dollars have tightened, valuations have recalibrated, and public markets have become increasingly selective. Yet the underlying need for innovation — particularly in oncology, rare disease, and CNS disorders — has never been greater. In this environment, the traditional biotech model of large internal teams, expensive wet-lab infrastructure, and long,

Summary Onconox Inc. has appointed biotech executive Geoff Muckle as CEO to strengthen the company’s leadership and drive OCN001 toward first-in-human studies in 2026. Geoff brings more than two decades of oncology and biotech experience spanning Roche, Champions Oncology, and Link Medical Solutions, and will lead the company’s evolution from a single-asset entity to a scalable platform-driven biotech. Onconox Inc., a biotechnology company developing precision, low-burden the